Integrating clinical, lab, and biopsy data to predict outcomes in acute alcoholic hepatitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective, multicenter observational analysis using the AP-HP clinical data warehouse to build prognostic models for acute alcoholic hepatitis diagnosed since 2017. The investigators will extract demographics, comorbidities, laboratory values (liver, renal, coagulation, lactate), histology details, microbiology results, medications, and outcomes including infections, transplantation, organ failure, and mortality. Statistical methods will include classical survival models (Cox regression, accelerated failure time models) and machine learning approaches such as random forests and gradient boosting to create integrative risk scores. The goal is to produce more accurate, personalized predictions of overall survival and to identify intermediate factors that modify prognosis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients (≥18 years)
* Diagnosis of acute alcoholic hepatitis (ICD10 K701 or occurrence of the terms "HAA" (French translation of "AAH" or "hépatite alcoolique aiguë" (French translation of "acute alcoholic hepatitis") in a pathology report, followed by manual verification

Exclusion Criteria:

\- Patients younger than 18 years at diagnosis

Where it's running

• Necker Hospital
  Paris, France Recruiting

Study contacts

• Principal investigator: Vincent MALLET — Assistance Publique - Hôpitaux de Paris
• Study coordinator: Vincent MALLET, MD, PhD
• Email: vincent.mallet@aphp.fr
• Phone: 01584142453

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Profiling gut bacteria in patients with severe alcoholic hepatitis

  This study is testing if the types of gut bacteria in patients with severe alcoholic hepatitis can help predict how well they respond to corticosteroid treatment, with or without fecal microbiota transplantation.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens, Picardie · NCT06159244

• HepQuant DuO blood test to track liver recovery after alcohol-related liver disease

  This tests whether the HepQuant DuO blood test can track liver recovery over one year in adults with alcohol-related liver disease or alcoholic hepatitis.

  Recruiting HepQuant, LLC · Redwood City, California · NCT07060547

• Prolonged steroids with NAC for severe alcoholic hepatitis

  This study tests whether adding N-acetylcysteine to prednisolone (or their placebos) improves outcomes for adults with severe alcoholic hepatitis.

  Recruiting Phase 3 University Hospital, Lille · Lille · NCT06956482

• TAK-242 and G-CSF in ACLF: a new treatment approach for adults with acute-on-chronic liver failure

  This trial tests whether adding TAK-242, with or without G-CSF, to standard ACLF care helps patients with severe alcoholic hepatitis and ACLF.

  Recruiting Phase 2 Yaqrit Ltd · London, Greater London · NCT06890039

• Exploring the role of gut bacteria in alcoholic hepatitis

  This study is trying to see how gut bacteria affect liver damage in people with severe alcoholic hepatitis to find new ways to help them feel better.

  Recruiting Hospices Civils de Lyon · Lyon · NCT06307964

• Treatment for Moderate Alcoholic Hepatitis

  This study is testing a new treatment called HA35 to see if it helps people with moderate alcoholic hepatitis feel better compared to a placebo.

  Recruiting Early Phase 1 The Cleveland Clinic · Cleveland, Ohio · NCT05018481

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.